Somedeb Ball

Has grant

Vanderbilt University Medical Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Medical Science Medical Science professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Aurora Kinase Inhibition to Drive Synergy and Overcome Resistance to Gilteritinib in FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia

Open Date: 2022-07-01

Close Date: 2023-06-01

Grant: Close

Prospective Evaluation of Racial and Gender Disparities in Clinical Outcomes, Quality of Life, and Financial Toxicity in Patients with Myelodysplastic Syndrome

Open Date: 2022-07-01

Close Date: 2023-06-01

Grant: Close

Evaluation of Racial and Gender Disparities in Disease Characteristics, Clinical Outcomes, and Health-related Quality of Life in Patients with Myelodysplastic Syndromes

Open Date: 2021-07-01

Close Date: 2022-06-01

Articles (22)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (3)

Luca Lanino

Humanitas University

ITALY

View details

MARTA SPREAFICO

Assistant Professor

Leiden University

NETHERLANDS

View details

Claudio Mosse

Chief

VA Tennessee Valley Healthcare System

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Somedeb Ball

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (22)

Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia

Venetoclax in combination with hypomethylating agents in chronic myelomonocytic leukemia: a propensity score matched multicenter cohort study

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes

Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes

Complete remission in a case of acute undifferentiated leukemia with novel combination therapy of FLAG-IDA and venetoclax

Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML

Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib

Mutations highly speci fi c for secondary <i>AML</i> are associated with poor outcomes in ELN favorable risk <i>NPM1</i>-mutated AML

Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia

Triple-Negative Myelofibrosis: Disease Features Response to Treatment and Outcomes

Safety and immunogenicity of a third dose of mRNA-1273 vaccine among cancer patients.

Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes.

Sex Disparities in Myelodysplastic Syndromes: Genotype, Phenotype, and Outcomes.

Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia.

Utilization of Serial Next-Generation Sequencing Among Patients Receiving CPX-351 for Newly Diagnosed Acute Myeloid Leukemia.

Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors among Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusion.

Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients.

TP53-altered higher-risk myelodysplastic syndromes/neoplasms and acute myeloid leukemia: a distinct genetic entity with unique unmet needs.

MPN-521 Somatic Mutational Landscape and Clinical Response to Upfront Targeted Tyrosine Kinase Inhibitors Among Patients With Myeloid and Lymphoid Neoplasms With Eosinophilia and Rearrangements of PDGFRA, PDGFRB, FGFR1, JAK2, or FLT3.

Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutations.

Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida.

Hypomethylating Agent and Venetoclax in Patients with Chronic Myelomonocytic Leukemia: Is the Combination Indeed Better?

Collaborators (3)

Luca Lanino

MARTA SPREAFICO

Claudio Mosse

Make your next move.